Companies ›Healthcare ›IMDX.O

IMDX.O — NASDAQ Pharmaceuticals & Medical Research

Insight Molecular Diagnostics Inc

$4,82

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

155,6M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-1 260,8 %

ROE

159,6 %

Net margin

-1 238,5 %

Debt / equity

-0,03

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$6,41

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Insight Molecular Diagnostics Inc develops and commercializes molecular diagnostic tests for infectious diseases, primarily focusing on rapid point-of-care testing solutions.

Business. Insight Molecular Diagnostics Inc (IMDX.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

BUY4 analysts

2 buy2 hold0 sell

Avg 12m price target8,33

Analyst recommendations

4 analysts · consensus Buy

Buy2

Hold2

Sell0

12-month price target

8,33

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

4 analysts · indicative

Ownership→

Vanguard Capital Management, LLC

largest disclosed fund holder

Profitability→

159,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning IMDX.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to IMDX.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Insight Molecular Diagnostics Inc (IMDX.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

AI synthesis

GENERATED

The company's capital structure shows a negative equity position of $31.5 million and a current ratio of 1.27, indicating limited short-term liquidity coverage. With $11.6 million in cash and $10.6 million in long-term debt, the liquidity position is constrained by $57.2 million in total liabilities. The negative net income of $50.2 million and operating loss of $51.1 million highlight significant operational challenges.

Profitability metrics show a return on equity of 1.5962 and return on assets of -1.9499, both well below industry benchmarks for biotechnology firms. The gross margin of 56.7% (calculated from $2.3 million gross profit on $4.1 million revenue) is strong but insufficient to offset operating costs. The debt-to-equity ratio of -0.03 reflects the negative equity position rather than leverage.

Geographic and segment exposure is not explicitly disclosed in the available data, but the company's focus appears to be on infectious disease diagnostics with a single product line. Revenue concentration in a single therapeutic area increases business risk.

The company's growth trajectory shows a revenue base of $4.1 million with no historical growth data available. Analysts have assigned a mean price target of $8.33, implying 67.9% upside from the current $4.96 market price. However, the negative operating cash flow of $22.2 million and free cash flow deficit of $51.2 million suggest significant near-term financial pressure.

Risk factors include the negative equity position, operating losses, and cash burn rate. The dilution risk is currently assessed as low, but the negative equity position could necessitate future capital raises. No immediate filing-based liquidity or dilution flags were detected in the available data.

Recent events include the publication of analyst price targets ranging from $4.00 to $12.00, with a mean recommendation of 2.50 (between buy and hold). No material filings or earnings transcripts were identified in the available data.

Key takeaways

The company has a negative equity position of $31.5 million and is burning $51.2 million in free cash flow annually
Despite a strong gross margin of 56.7%, the company is generating significant operating losses
Analysts see potential with a mean price target of $8.33, but the current valuation implies high risk
The negative equity position and cash burn rate create significant near-term financial pressure
No immediate liquidity or dilution flags were detected, but the capital structure is highly leveraged
"margin_outlook_rationale": "The company's gross margin of 56.7% is strong but insufficient to cover operating costs given the current revenue scale",

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$4,82

Market cap

$160.1M

Enterprise valueⓘ

$149.6M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

-$31.5M

Net cashⓘ

$10.5M

Current ratioⓘ

1.3

Debt / equityⓘ

-0.0

ROAⓘ

-1.9%

ROEⓘ

1.6%

Cash conversionⓘ

44.0%

CapEx / revenueⓘ

-78.5%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures

Partners1

Bio-rad LaboratoriesBIO.OPartner95%Source ↗

Supply chain

Vendors → IMDX ↔ Partners → Customers · click any node to drill

1 mention in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

Peer comparison8 peers · vs IMDX · multiples and returns

KLAR—

KLAR.ST

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BNTX—

Biontech SE

$92,25

23,3B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EXEL—

Exelixis Inc

$55,06

14,7B USD

P/E

19,5x

— vs self

Div yield

—

— vs self

ROE

40,4 %

-119,2 vs self

MDGL—

Madrigal Pharmaceuticals Inc

$482,00

11,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-47,8 %

-207,4 vs self

INSM—

Insmed Inc

$107,46

23,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-160,2 %

-319,8 vs self

VCYT—

Veracyte Inc

$45,30

3,6B USD

P/E

55,5x

— vs self

Div yield

—

— vs self

ROE

5,1 %

-154,6 vs self

MDXG—

Mimedx Group Inc

$4,27

636,0M USD

P/E

11,1x

— vs self

Div yield

—

— vs self

ROE

18,9 %

-140,7 vs self

AVIR—

Atea Pharmaceuticals Inc

$4,61

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

-57,5 %

-217,1 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,95

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-10 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,95
Revenue	—no estimate	—no estimate	2,6M USD
Operating income	—no estimate	—no estimate	-30,6M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy0

Buy2

Hold2

Sell0

Strong sell0

12-month price target$8,33 · Median $9,00

Low $4,00High $12,00

Operating income · consensus-30,6M USD

EPS surprise

−74,3 %

reported vs consensus · miss

Revenue surprise

+57,5 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$4,00

Mean$8,33

Median$9,00

High$12,00

Spot$4,82

+72.9 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-1 260,8 %Below median

Net Margin-1 238,5 %Below median

ROE159,6 %Best in class

Capex / Rev-78,5 %Bottom quartile

D/E-0,03Above P75

Cash Conv0,44Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 621 239 sh3 exercises · 3 grants3 insiders

James Andrea S.Chief Financial Officer · Restricted Stock Units → Common StockDisposed 28 302exercise · 2026-03-26
Liu James YangVP ACCT, Cntlr, Treasurer, PAO · Restricted Stock Units → Common StockDisposed 6 289exercise · 2026-03-26
Riggs JoshDirector, CEO and President · Restricted Stock Units → Common StockDisposed 47 170exercise · 2026-03-26
James Andrea S.Chief Financial Officer · Restricted Stock Units → Common StockAcquired 50 000disposition · 2025-10-31
Riggs JoshDirector, CEO and President · Option to Purchase Common Stock → Common StockAcquired 400 000 @ $3,33grant · 2025-09-28
James Andrea S.Chief Financial Officer · Option to Purchase Common Stock → Common StockAcquired 235 000 @ $3,33grant · 2025-09-28
Liu James YangVP ACCT, Cntlr, Treasurer, PAO · Option to Purchase Common Stock → Common StockAcquired 18 000 @ $3,33grant · 2025-09-28

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

Insight Molecular Diagnostics Inc Market data — financials · 2026-05-28
Insight Molecular Diagnostics Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$4M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M

Leadership

Joshua RiggsPresident, Chief Executive Officer, Director

Insider activity

Net buying14 buys · 0 sellsnet $5,7M7 insiders · last 365d

Last Andrew J.Director · Common Stock, no par valueOther 7 700 @ $5,69$44K · 2026-07-01
SILVERMAN LOUDirector · Common Stock, no par valueOther 7 700 @ $5,69$44K · 2026-07-01
Arno AndrewDirector · Common Stock, no par valueOther 12 100 @ $5,69$69K · 2026-07-01
Last Andrew J.Director · Common Stock, no par valueOther 26 943 · 2026-06-11
SILVERMAN LOUDirector · Common Stock, no par valueOther 26 943 · 2026-06-11
Arno AndrewDirector · Common Stock, no par valueOther 32 331 · 2026-06-11
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 0 · 2026-04-27
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 250 923 @ $3,64$913K · 2026-04-27
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 38 880 @ $3,53$137K · 2026-04-24
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 0 · 2026-04-24
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 0 · 2026-04-23
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 280 381 @ $3,50$982K · 2026-04-23
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 0 · 2026-04-20
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 40 690 @ $3,88$158K · 2026-04-20
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 0 · 2026-04-17
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 40 114 @ $3,57$143K · 2026-04-17
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 0 · 2026-04-16
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 102 057 @ $3,45$352K · 2026-04-16
James Andrea S.Chief Financial Officer · Common StockOther 11 298 @ $4,11$46K · 2026-03-26
Liu James YangVP ACCT, Cntlr, Treasurer, PAO · Common StockOther 6 289 · 2026-03-26
Liu James YangVP ACCT, Cntlr, Treasurer, PAO · Common StockOther 2 578 @ $4,11$11K · 2026-03-26
Riggs JoshDirector, CEO and President · Common StockOther 12 310 @ $4,11$51K · 2026-03-26
Riggs JoshDirector, CEO and President · Common StockOther 47 170 · 2026-03-26
James Andrea S.Chief Financial Officer · Common StockOther 28 302 · 2026-03-26
BROADWOOD PARTNERS, L.P.10% owner · Common Stock, no par valueBought 521 739 @ $5,75$3,0M · 2026-02-10

Short positioning

1.2Mshares short+23.7% vs prior

4.34days to cover

46.2%short of daily vol

5.0Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

IMDX.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorPartners

Evidence & claims

From filings & derived data

Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 20.8%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 66.2%Derived (calculated)
Net margin (FY 2025-12-31): -1.2%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 64.6%Derived (calculated)
Return on equity (FY 2025-12-31): 0.2%Derived (calculated)
Gross margin (FY 2025-12-31): 56.7%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -26.6%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -156.3%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 115.6%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 61.6%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 16.2%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -7.2%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 17.2%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 210.5%Derived (calculated)
Return on assets (FY 2025-12-31): -0.2%Derived (calculated)
Debt-to-equity (FY 2025-12-31): -1.82xDerived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 64.6%Derived (calculated)
Current ratio (FY 2025-12-31): 1.27xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 517.2%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 34.1%Derived (calculated)
Current liabilities (annual): USD 12.07MSEC XBRL filing
Shareholders' equity (annual): USD -31.46MSEC XBRL filing
Current assets (annual): USD 15.31MSEC XBRL filing
Shares outstanding (annual): 28.68MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-01INSIDERLast Andrew J. transacted 7.7k sh Common Stock, no par value — Director ~$44k

2026-07-01INSIDERSILVERMAN LOU transacted 7.7k sh Common Stock, no par value — Director ~$44k

2026-07-01INSIDERArno Andrew transacted 12.1k sh Common Stock, no par value — Director ~$69k

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated

2026-06-17FILING8-K filing →

2026-06-11 00:00 UTCINSIDER3 insider transactions — 2026-06

2026-06-11INSIDERLast Andrew J. transacted 26.9k sh Common Stock, no par value — Director

2026-06-11INSIDERSILVERMAN LOU transacted 26.9k sh Common Stock, no par value — Director

2026-06-11INSIDERArno Andrew transacted 32.3k sh Common Stock, no par value — Director

2026-05-13FILING10-Q filing →

2026-05-13FILING8-K filing →

2026-04-30FILINGDEF 14A filing →

2026-04-30FILING8-K filing →

2026-04-27 00:00 UTCINSIDER12 insider transactions — 2026-04 · net buy $2.7M

2026-04-27INSIDERBROADWOOD PARTNERS, L.P. bought 0 sh Common Stock, no par value — 10% owner

2026-04-27INSIDERBROADWOOD PARTNERS, L.P. bought 250.9k sh Common Stock, no par value — 10% owner ~$913k

2026-04-24INSIDERBROADWOOD PARTNERS, L.P. bought 38.9k sh Common Stock, no par value — 10% owner ~$137k

2026-04-24INSIDERBROADWOOD PARTNERS, L.P. bought 0 sh Common Stock, no par value — 10% owner

2026-04-23INSIDERBROADWOOD PARTNERS, L.P. bought 0 sh Common Stock, no par value — 10% owner

2026-04-23INSIDERBROADWOOD PARTNERS, L.P. bought 280.4k sh Common Stock, no par value — 10% owner ~$982k

2026-04-20INSIDERBROADWOOD PARTNERS, L.P. bought 0 sh Common Stock, no par value — 10% owner

2026-04-20INSIDERBROADWOOD PARTNERS, L.P. bought 40.7k sh Common Stock, no par value — 10% owner ~$158k

2026-04-17INSIDERBROADWOOD PARTNERS, L.P. bought 0 sh Common Stock, no par value — 10% owner

2026-04-17INSIDERBROADWOOD PARTNERS, L.P. bought 40.1k sh Common Stock, no par value — 10% owner ~$143k

2026-04-16INSIDERBROADWOOD PARTNERS, L.P. bought 0 sh Common Stock, no par value — 10% owner

2026-04-16INSIDERBROADWOOD PARTNERS, L.P. bought 102.1k sh Common Stock, no par value — 10% owner ~$352k

2026-03-26 00:00 UTCINSIDER9 insider transactions — 2026-03 · net sell $108k 3 derivative

2026-03-26FILING10-K filing →

2026-03-26FILING8-K filing →

2026-03-26INSIDERJames Andrea S. transacted 11.3k sh — Chief Financial Officer ~$46k

2026-03-26INSIDERLiu James Yang transacted 6.3k sh — VP ACCT, Cntlr, Treasurer, PAO

2026-03-26INSIDERLiu James Yang transacted 2.6k sh — VP ACCT, Cntlr, Treasurer, PAO ~$11k

2026-03-26INSIDERRiggs Josh transacted 12.3k sh — Director, CEO and President ~$51k

Showing the 40 most recent of 57 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread